Blueprint Medicines

94 articles with Blueprint Medicines

• Blueprint Medicines to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021

  7/22/2021

   Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday , July 29, 2021 to report its second quarter 2021 financial results and provide a corporate update.

• Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - July 07, 2021

  7/7/2021

  Blueprint Medicines Corporation announced that, effective on July 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 25,762 shares of its common stock and an aggregate of 12,880 restricted stock units to 12 new employees under Blueprint Medicines' 2020 Inducement Plan.

• 

  Rare Blood Disease Drug Win Marks Fourth Approval for Blueprint Medicines

  6/17/2021

  The U.S. FDA approved Ayvakit for the treatment of adult patients with advanced sytematic mastocytosis (SM), advanced SM, and mast cell leukemia. 
• 

  FDA Action Alert: Blueprint, Orphazyme and Eton

  6/14/2021

  The month of June continues to be busy for the U.S. Food and Drug Administration. There are three PDUFA dates on the calendar for this week. Here’s a look.

• Blueprint Medicines Presents ARROW Trial Data for GAVRETO® (pralsetinib) Highlighting Durable Clinical Activity in Patients with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer and Other Advanced Solid Tumors

  5/19/2021

  88% ORR and median duration of response not reached in treatment-naïve patients with non-small cell lung cancer enrolled after expansion of trial inclusion criteria to include patients eligible for standard-of-care front-line therapy

• Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 05, 2021

  5/5/2021

  Blueprint Medicines Corporation announced that, effective on May 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 21,045 shares of its common stock and an aggregate of 10,520 restricted stock units to 13 new employees under Blueprint Medicines' 2020 Inducement Plan.

• Blueprint Medicines Reports First Quarter 2021 Financial Results

  4/29/2021

  -- 7 research- and clinical-stage programs highlighted at AACR, including recently nominated development candidate with best-in-class potential targeting CDK2 -- -- GAVRETO® (pralsetinib) becomes the first selective RET inhibitor approved in China; AYVAKIT™/AYVAKYT® (avapritinib) becomes the first precision therapy for patients with PDGFRA exon 18 mutant GIST in China --

• Blueprint Medicines to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021

  4/22/2021

  Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, April 29, 2021 to report its first quarter 2021 financial results and provide a corporate update.

• Blueprint Medicines Data Highlight Clinical Leadership in Systemic Mastocytosis at AACR Annual Meeting 2021

  4/11/2021

  New patient-reported outcomes data from PATHFINDER trial show AYVAKIT significantly reduced disease symptoms and improved quality of life

• Blueprint Medicines Presents Preclinical Data Highlighting Broad Precision Therapy Research Pipeline at AACR Annual Meeting 2021

  4/10/2021

  Blueprint Medicines Corporation announced data from multiple poster presentations highlighting the breadth of the company's precision therapy pipeline at the virtual American Association for Cancer Research Annual Meeting 2021.

• Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Apr 07, 2021

  4/7/2021

  Blueprint Medicines Corporation announced that, effective on April 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 27,543 shares of its common stock and an aggregate of 13,792 restricted stock units to 14 new employees under Blueprint Medicines' 2020 Inducement Plan.

• Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Mar 05, 2021

  3/5/2021

  Blueprint Medicines Corporation announced that, effective on March 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 15,474 shares of its common stock and an aggregate of 7,736 restricted stock units to nine new employees under Blueprint Medicines' 2020 Inducement Plan.

• Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results

  2/17/2021

  -- Supplemental NDA accepted by FDA for AYVAKIT™ (avapritinib) for advanced systemic mastocytosis -- -- Type II variation MAA submitted to EMA for AYVAKYT® (avapritinib) for advanced systemic mastocytosis -- -- Announced a potential best-in-class research program targeting CDK2 for the treatment of multiple cancers with tumor-associated cell cycle defects --

• Blueprint Medicines to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 17, 2021

  2/10/2021

   Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, systemic mastocytosis, and cancer immunotherapy, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, February 17, 2021 to report its fourth quarter

• Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Feb 05, 2021

  2/5/2021

  Blueprint Medicines Corporation, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, announced that, effective on February 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 15,226 shares of its common stock and an aggregate of 7,613 restricted stock units to eight new employees under Blueprint Medicines' 2020 Inducement Plan.

• Blueprint Medicines Reports Portfolio Milestones and Outlines 2021 Roadmap for Precision Medicine Leadership

  1/11/2021

  -- AYVAKIT™ (avapritinib) granted FDA breakthrough therapy designation for the treatment of moderate to severe indolent systemic mastocytosis -- -- Positive top-line results from Phase 1 healthy volunteer trial of BLU-263 support plans to initiate Phase 2 HARBOR trial in non-advanced systemic mastocytosis in mid-2021 -- -- Nominated potential first-in-class development candidate targeting double-mutant EGFR, deepening leadership in lung cancer --

• Blueprint Medicines Announces R&D Leadership Transitions

  1/11/2021

  -- Becker Hewes, M.D., promoted to Chief Medical Officer -- -- Andy Boral, M.D., Ph.D., to transition from Chief Medical Officer to Executive Vice President, Clinical Development -- -- Marion Dorsch, Ph.D., Chief Scientific Officer, to depart the company

• Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Jan 05, 2021

  1/5/2021

  Blueprint Medicines Corporation announced that, effective on January 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 7,675 shares of its common stock and an aggregate of 3,837 restricted stock units to three new employees under Blueprint Medicines' 2020 Inducement Plan.

• Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Dec 04, 2020

  12/4/2020

  Blueprint Medicines Corporation announced that, effective on December 1, 2020, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 16,354 shares of its common stock and an aggregate of 8,174 restricted stock units to eight new employees under Blueprint Medicines' 2020 Inducement Plan.

• Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer

  12/1/2020

  -- Once-daily treatment with GAVRETO demonstrated robust efficacy in patients with RET-altered thyroid cancers, including prolonged duration of response -- -- Expands GAVRETO label following initial approval for RET fusion-positive non-small cell lung cancer in September 2020 -- -- Blueprint Medicines and Genentech are co-commercializing GAVRETO in the U.S. --